Clinical Research Directory
Browse clinical research sites, groups, and studies.
Angiotensin II in Liver Transplantation
Sponsor: University of California, San Francisco
Summary
The purpose of this study is to determine the efficacy and safety of Angiotensin II as a second-line vasopressor (drug that raises the blood pressure) during liver transplantation.
Official title: Angiotensin II in Liver Transplantation (AngLT-1): A Pilot Randomized Controlled Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2022-06-28
Completion Date
2027-03-18
Last Updated
2026-03-20
Healthy Volunteers
No
Interventions
Angiotensin II
Infusion of Angiotensin II initiated if participants require norepinephrine at a rate of \> 0.05 mcg/kg/min. The infusion will be titrated no more frequently than every 10 minutes during liver transplantation as a second line vasopressor and discontinued prior to leaving the operating room when the surgery is complete.
Saline
Infusion of 0.9% saline initiated if participants require norepinephrine at a rate of \> 0.05 mcg/kg/min. The infusion will be titrated no more frequently than every 10 minutes during liver transplantation as a second line vasopressor and discontinued prior to leaving the operating room when the surgery is complete.
Locations (1)
University of California, San Francisco
San Francisco, California, United States